Phase 2a proof-of concept clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease (DKD) ...

Select ARO-INHBE Preclinical Results: In a diet-induced obese (DIO) mouse model, hepatic INHBE silencing with siRNA led to a 19% suppression in body weight gain relative to vehicle controls.

In preparation for filing an IND for IC 100, planned for second half of 2025, we will initiate two diet-induced obesity (DIO) mouse model studies, with the first planned to begin in H1-2025.

In a diet-induced obese (DIO) mouse model, hepatic INHBE silencing with siRNA led to a 19% suppression in body weight gain relative to vehicle controls. Treated mice exhibited improved body ...

In preparation for filing an IND for IC 100, planned for second half of 2025, we will initiate two diet-induced obesity (DIO) mouse model studies, with the first planned to begin in H1-2025. The ...